Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept

Am J Psychiatry. 2016 Dec 1;173(12):1239-1241. doi: 10.1176/appi.ajp.2016.16080868.

¹ From the Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif.; the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.; the Department of Psychology, The Hebrew University of Jerusalem, Israel; the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the New York State Psychiatric Institute, New York; Aptinyx, Evanston, Ill.; and the Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, Ill.

No abstract available

Keywords: AMPA; Clinical Drug Studies; GLYX-13; Ketamine; NMDA; OCD; Obsessive-Compulsive Disorder; Rapastinel.

Publication types